<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for http://feeds.benzinga.com/benzinga</title><link>http://feeds.benzinga.com/benzinga</link><description>Individual feed output.</description><lastBuildDate>Fri, 01 Aug 2025 10:56:32 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Celestica, Inc. (CLS) is Attracting Investor Attention: Here is What You Should Know</title><link>https://www.benzinga.com/node/46796656</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture7.png</image_url><description>Celestica (NYSE: CLS ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factor...</description><pubDate>Fri, 01 Aug 2025 15:33:23 GMT</pubDate></item><item><title>$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today</title><link>https://www.benzinga.com/insights/news/25/08/46796428/1000-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture4.png</image_url><description>read more</description><pubDate>Fri, 01 Aug 2025 15:30:26 GMT</pubDate></item><item><title>4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study</title><link>https://www.benzinga.com/news/health-care/25/08/46796384/4d-molecular-therapeutics-rallies-on-heels-of-diabetes-related-vision-study</link><image_url>https://cdn.benzinga.com/files/images/story/2025/08/01/Macro-Photo-Of-Woman-With-Beautiful-Eyes.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment. read more</description><pubDate>Fri, 01 Aug 2025 15:29:21 GMT</pubDate></item><item><title>LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People</title><link>https://www.benzinga.com/news/fda/25/08/46796085/lenz-therapeutics-eye-drop-scores-first-fda-approval-for-age-related-blurred-vision-condition-impacting-</link><image_url>https://cdn.benzinga.com/files/images/story/2025/08/01/Presbyopia-eye-condition.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025. read more</description><pubDate>Fri, 01 Aug 2025 15:25:51 GMT</pubDate></item><item><title>Exxon Mobil Hits Record Production, CEO Reaffirms Hunt For Value-Driven Deals</title><link>https://www.benzinga.com/markets/earnings/25/08/46795989/exxon-mobil-hits-record-production-ceo-reaffirms-hunt-for-value-driven-deals</link><image_url>https://cdn.benzinga.com/files/images/story/2025/08/01/Trinidad--Co--Usa---May-19--2024-Exxon-G.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>Exxon Mobil Corp. (XOM) Q2 earnings beat estimates with $7.1B profit on record production and revenues, plans for growth and acquisitions. read more</description><pubDate>Fri, 01 Aug 2025 15:22:51 GMT</pubDate></item></channel></rss>